Latest Pharma Insights
People On The Move: Appointments At Engelhard, Schwabe, Klosterfrau
A round-up of the latest European consumer health people moves: Engelhard names chief commercial strategy officer; Schwabe appoints head of new unit; Klosterfrau gets sustainability lead.
HBW Insight - February 10, 2026
A round-up of the latest European consumer health people moves: Engelhard names chief commercial strategy officer; Schwabe appoints head of new unit; Klosterfrau gets sustainability lead.
HBW Insight - February 10, 2026
Aerska Builds Cashpile To Advance Brain Shuttle Tech
The Irish firm has raised a total of $60m to develop its antibody-oligonucleotide conjugate platform.
Scrip - February 10, 2026
The Irish firm has raised a total of $60m to develop its antibody-oligonucleotide conjugate platform.
Scrip - February 10, 2026
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity
The UK-headquartered firm remains on track to hit $80bn in sales by 2030, but must still convince investors that it can be a major obesity market player in the following decade.
Scrip - February 10, 2026
The UK-headquartered firm remains on track to hit $80bn in sales by 2030, but must still convince investors that it can be a major obesity market player in the following decade.
Scrip - February 10, 2026
Lupin Strikes $90m Settlement With Astellas On Myrbetriq
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Generics Bulletin - February 10, 2026
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Generics Bulletin - February 10, 2026
Philips Sets 3-Year Growth Plan And Ends 2025 On A Comparative High
Royal Philips’ 2025 2% comparable sales growth points to a company emerging from its respiratory recall depths and ready to give a vote of confidence to the CEO as a new three-year financial plan is unveiled.
Medtech Insight - February 10, 2026
Royal Philips’ 2025 2% comparable sales growth points to a company emerging from its respiratory recall depths and ready to give a vote of confidence to the CEO as a new three-year financial plan is unveiled.
Medtech Insight - February 10, 2026
Fresenius Kabi And Phlow Partner On End-To-End US Epinephrine Supply Chain
Phlow and Fresenius Kabi are partnering in the US to establish a fully domestic manufacturing pathway for epinephrine injection, with launch targeted for 2027 pending approvals. The collaboration is aimed at addressing the current lack of a US-based API producer.
Generics Bulletin - February 10, 2026
Phlow and Fresenius Kabi are partnering in the US to establish a fully domestic manufacturing pathway for epinephrine injection, with launch targeted for 2027 pending approvals. The collaboration is aimed at addressing the current lack of a US-based API producer.
Generics Bulletin - February 10, 2026
Organon And Henlius Settle US Perjeta Litigation
Organon and Henlius have agreed to settle US litigation with Roche and Genentech over their Poherdy pertuzumab biosimilar rival to Perjeta. But when will they launch?
Generics Bulletin - February 10, 2026
Organon and Henlius have agreed to settle US litigation with Roche and Genentech over their Poherdy pertuzumab biosimilar rival to Perjeta. But when will they launch?
Generics Bulletin - February 10, 2026
gMyrbetriq: Lupin Settles With Astellas, Zydus Says Court Directed Mirabegron Mediation
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Scrip - February 10, 2026
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Scrip - February 10, 2026
Stock Watch: Pfizer Navigates Vaccine Gains And Acquisition Pains
Global pharmaceutical operations can feel like a marathon slog as products launch in an environment of competitive and political pressures. Pfizer illustrated that overpaying for the wrong acquisition without proper due diligence may impede that hard-fought operational progress.
Scrip - February 10, 2026
Global pharmaceutical operations can feel like a marathon slog as products launch in an environment of competitive and political pressures. Pfizer illustrated that overpaying for the wrong acquisition without proper due diligence may impede that hard-fought operational progress.
Scrip - February 10, 2026
PCH Still Looking Ahead For Clear Eyes Restocking With Production, Supply Pieces In Place
Returning to full Clear Eyes production and distribution and brand’s previous revenue levels aren’t expected within PCH’s current fiscal year, which ends in March; additional marketing spend expected.
HBW Insight - February 10, 2026
Returning to full Clear Eyes production and distribution and brand’s previous revenue levels aren’t expected within PCH’s current fiscal year, which ends in March; additional marketing spend expected.
HBW Insight - February 10, 2026
Cosmetics Europe Braces for ‘Tough’ Talks to Preserve Risk-Based Framework in EU Omnibus
A proposed hazard-based regulatory framework may complicate the opportunity for Europe’s cosmetics industry to show that cosmetic ingredients and products are safe.
HBW Insight - February 10, 2026
A proposed hazard-based regulatory framework may complicate the opportunity for Europe’s cosmetics industry to show that cosmetic ingredients and products are safe.
HBW Insight - February 10, 2026
Aerska Builds Cashpile To Advance Brain Shuttle Tech
The Irish firm has raised a total of $60m to develop its antibody-oligonucleotide conjugate platform.
Scrip - February 10, 2026
The Irish firm has raised a total of $60m to develop its antibody-oligonucleotide conjugate platform.
Scrip - February 10, 2026
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity
The UK-headquartered firm remains on track to hit $80bn in sales by 2030, but must still convince investors that it can be a major obesity market player in the following decade.
Scrip - February 10, 2026
The UK-headquartered firm remains on track to hit $80bn in sales by 2030, but must still convince investors that it can be a major obesity market player in the following decade.
Scrip - February 10, 2026
gMyrbetriq: Lupin Settles With Astellas, Zydus Says Court Directed Mirabegron Mediation
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Scrip - February 10, 2026
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Scrip - February 10, 2026
Stock Watch: Pfizer Navigates Vaccine Gains And Acquisition Pains
Global pharmaceutical operations can feel like a marathon slog as products launch in an environment of competitive and political pressures. Pfizer illustrated that overpaying for the wrong acquisition without proper due diligence may impede that hard-fought operational progress.
Scrip - February 10, 2026
Global pharmaceutical operations can feel like a marathon slog as products launch in an environment of competitive and political pressures. Pfizer illustrated that overpaying for the wrong acquisition without proper due diligence may impede that hard-fought operational progress.
Scrip - February 10, 2026
Philips Sets 3-Year Growth Plan And Ends 2025 On A Comparative High
Royal Philips’ 2025 2% comparable sales growth points to a company emerging from its respiratory recall depths and ready to give a vote of confidence to the CEO as a new three-year financial plan is unveiled.
Medtech Insight - February 10, 2026
Royal Philips’ 2025 2% comparable sales growth points to a company emerging from its respiratory recall depths and ready to give a vote of confidence to the CEO as a new three-year financial plan is unveiled.
Medtech Insight - February 10, 2026
People On The Move: Appointments At Engelhard, Schwabe, Klosterfrau
A round-up of the latest European consumer health people moves: Engelhard names chief commercial strategy officer; Schwabe appoints head of new unit; Klosterfrau gets sustainability lead.
HBW Insight - February 10, 2026
A round-up of the latest European consumer health people moves: Engelhard names chief commercial strategy officer; Schwabe appoints head of new unit; Klosterfrau gets sustainability lead.
HBW Insight - February 10, 2026
PCH Still Looking Ahead For Clear Eyes Restocking With Production, Supply Pieces In Place
Returning to full Clear Eyes production and distribution and brand’s previous revenue levels aren’t expected within PCH’s current fiscal year, which ends in March; additional marketing spend expected.
HBW Insight - February 10, 2026
Returning to full Clear Eyes production and distribution and brand’s previous revenue levels aren’t expected within PCH’s current fiscal year, which ends in March; additional marketing spend expected.
HBW Insight - February 10, 2026
Cosmetics Europe Braces for ‘Tough’ Talks to Preserve Risk-Based Framework in EU Omnibus
A proposed hazard-based regulatory framework may complicate the opportunity for Europe’s cosmetics industry to show that cosmetic ingredients and products are safe.
HBW Insight - February 10, 2026
A proposed hazard-based regulatory framework may complicate the opportunity for Europe’s cosmetics industry to show that cosmetic ingredients and products are safe.
HBW Insight - February 10, 2026
Lupin Strikes $90m Settlement With Astellas On Myrbetriq
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Generics Bulletin - February 10, 2026
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
Generics Bulletin - February 10, 2026
Fresenius Kabi And Phlow Partner On End-To-End US Epinephrine Supply Chain
Phlow and Fresenius Kabi are partnering in the US to establish a fully domestic manufacturing pathway for epinephrine injection, with launch targeted for 2027 pending approvals. The collaboration is aimed at addressing the current lack of a US-based API producer.
Generics Bulletin - February 10, 2026
Phlow and Fresenius Kabi are partnering in the US to establish a fully domestic manufacturing pathway for epinephrine injection, with launch targeted for 2027 pending approvals. The collaboration is aimed at addressing the current lack of a US-based API producer.
Generics Bulletin - February 10, 2026
Organon And Henlius Settle US Perjeta Litigation
Organon and Henlius have agreed to settle US litigation with Roche and Genentech over their Poherdy pertuzumab biosimilar rival to Perjeta. But when will they launch?
Generics Bulletin - February 10, 2026
Organon and Henlius have agreed to settle US litigation with Roche and Genentech over their Poherdy pertuzumab biosimilar rival to Perjeta. But when will they launch?
Generics Bulletin - February 10, 2026
From CF To Big Pulmonary Markets: SpliSense’s Strategy To Make Inhaled RNA Work
SpliSense is the first company to show inhaled antisense oligos improve lung function in cystic fibrosis, validating its platform for larger COPD and asthma markets.
In Vivo - February 9, 2026
SpliSense is the first company to show inhaled antisense oligos improve lung function in cystic fibrosis, validating its platform for larger COPD and asthma markets.
In Vivo - February 9, 2026
Deal-Making Quarterly Statistics, Q4 2025
During Q4, biopharma merger and acquisition deal value reached $94.8bn and drew in $74.7bn in potential deal value from alliances. Device company M&A values reached $3.5bn, while in vitro diagnostics and research tools players’ M&A activity totaled $39.8m.
In Vivo - February 9, 2026
During Q4, biopharma merger and acquisition deal value reached $94.8bn and drew in $74.7bn in potential deal value from alliances. Device company M&A values reached $3.5bn, while in vitro diagnostics and research tools players’ M&A activity totaled $39.8m.
In Vivo - February 9, 2026
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build
Biogen’s president and head of North America talked to Scrip about the company’s commercial expansion into new areas in immunology and nephrology.
In Vivo - February 9, 2026
Biogen’s president and head of North America talked to Scrip about the company’s commercial expansion into new areas in immunology and nephrology.
In Vivo - February 9, 2026